Crispr Theraptc (NASDAQ:CRSP) has been given an average recommendation of “Buy” by the eight research firms that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $21.92.

A number of equities analysts recently weighed in on CRSP shares. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Cann started coverage on Crispr Theraptc in a report on Monday, July 17th. They issued a “market perform” rating for the company. Finally, SunTrust Banks, Inc. started coverage on Crispr Theraptc in a report on Thursday, July 13th. They issued a “hold” rating and a $16.00 price target for the company.

Shares of Crispr Theraptc (NASDAQ:CRSP) opened at 18.40 on Monday. The company’s 50 day moving average price is $16.34 and its 200 day moving average price is $17.57. The stock’s market cap is $735.94 million. Crispr Theraptc has a 52-week low of $11.63 and a 52-week high of $25.00.

Crispr Theraptc (NASDAQ:CRSP) last issued its quarterly earnings data on Thursday, May 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.06. The company had revenue of $2.70 million during the quarter. On average, analysts anticipate that Crispr Theraptc will post ($2.46) earnings per share for the current year.

In related news, CEO Rodger Novak sold 3,650 shares of the company’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $15.02, for a total value of $54,823.00. Following the completion of the transaction, the chief executive officer now owns 1,218,655 shares of the company’s stock, valued at approximately $18,304,198.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kurt Von Emster sold 5,512 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $17.51, for a total value of $96,515.12. The disclosure for this sale can be found here. Insiders sold a total of 442,864 shares of company stock valued at $7,393,640 in the last ninety days. 39.98% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of CRSP. IHT Wealth Management LLC purchased a new stake in Crispr Theraptc during the first quarter valued at approximately $110,000. Credit Suisse AG purchased a new stake in Crispr Theraptc during the first quarter valued at approximately $1,742,000. Paulson & CO. Inc. purchased a new stake in Crispr Theraptc during the first quarter valued at approximately $1,099,000. Monashee Investment Management LLC raised its stake in Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares during the period. Finally, Wellington Management Group LLP raised its stake in Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the period. Institutional investors own 24.08% of the company’s stock.

WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/07/crispr-theraptc-nasdaqcrsp-given-consensus-recommendation-of-buy-by-brokerages.html.

Crispr Theraptc Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Analyst Recommendations for Crispr Theraptc (NASDAQ:CRSP)

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.